Reuters logo
BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist
2017年10月19日 / 中午12点06分 / 1 个月前

BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

Oct 19 (Reuters) - Dynavax Technologies Corp

* Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy

* Dynavax Technologies - ‍dose escalation study is expected to enroll about 24 patients in 5 cohorts with advanced NSCLC Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below